What are the side effects of Livdelzi (Seladelpar)?

Livdelzi (Seladelpar) is an oral prescription medicine primarily used to treat primary cholangitis (PBC) in adults. It is particularly suitable for adults who have a poor response to ursodeoxycholic acid (UDCA) or patients who cannot tolerate UDCA and can be used alone. The drug manages PBC by activating specific receptors that play important roles in key physiological processes such as bile acid synthesis, inflammation, fibrosis, and lipid metabolism. By reducing bile acid production, Seladelpar can alleviate liver damage caused by bile acid accumulation.

When using Livdelzi, patients need to be aware of possible adverse reactions. According to clinical trial data, common side effects reported include headache, abdominal pain, nausea, bloating, and dizziness, all occurring at rates above 5% in the placebo group. In addition, there are some warnings and precautions for Livdelzi, such as the risk of fractures, abnormal liver function, and caution in patients with biliary obstruction.

AlthoughLivdelzi has a certain therapeutic effect on PBC patients, it is not yet clear whether the drug can significantly improve the survival rate of patients or effectively prevent liver decompensation. Therefore, before using Livdelzi for treatment, doctors usually comprehensively evaluate the patient's specific situation to ensure that the most appropriate treatment plan is selected, while closely monitoring the side effects of the drug and the patient's liver function.

Overall,Livdelzi, as a new treatment drug, provides a new treatment option for PBC patients, especially those who have poor response to traditional treatments. However, patients must maintain close communication with medical professionals when taking this drug to respond to possible side effects and health risks in a timely manner.